New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
04:55 EDTFCSC, FCSC, FCSC, SNY, SNY, SNY, GSK, GSK, GSK, NVS, NVS, NVS, PFE, PFE, PFE, SAFC, SAFC, SAFC, CLDX, CLDX, CLDX, CELG, CELG, CELG, WX, WX, WX, XON, XON, XON, OPXA, OPXA, OPXA, BLUE, BLUE, BLUE, BIIB, BIIB, BIIBPhacilitate to hold a forum
Cell & Gene Therapy Forum 2014 is being held in Washington, D.C. on January 27-29.
News For FCSC;BLUE;OPXA;XON;WX;CELG;CLDX;SAFC;PFE;NVS;GSK;SNY;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 19, 2015
06:21 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill
05:31 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill
February 18, 2015
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
February 17, 2015
15:36 EDTPFETianyin JCM plans for FDA certification process
Tianyin Pharmaceutical (TPI) updated on the business and development at its Jiangchuan Macrolide Facility, or JCM, active pharmaceutical ingredients operation. In addition to JCM's certification at India, along with other international clients located at Bangladesh, Philippines and Iran on import status, TPI plans for FDA certification process at its JCM facility in order to service international clients such as Pfizer's (PFE) and their subsidiaries in China, the company said. "This is expected to translate to further demand for JCM's macrolide API business in both the domestic and international markets," Tianyin stated.
11:38 EDTSNYGenzyme reports publication of ENGAGE registration study results
Subscribe for More Information
10:01 EDTPFECVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
08:04 EDTWXWuXi PharmaTech sees FY15 capital spending of $200M
Subscribe for More Information
08:04 EDTWXWuXi PharmaTech enters into loan agreement with consortium led by Citi
Subscribe for More Information
07:38 EDTGSKGlaxo replaces head of struggling U.S. drug unit, Bloomberg reports
Subscribe for More Information
February 13, 2015
11:31 EDTNVSNovartis says heart failure medicine LCZ696 granted FDA piority review
Novartis announced that the U.S. FDA has granted priority review designation to LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction. The designation accelerates the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition[4]. For LCZ696 this reduces the total review time from 12 to 8 months, meaning the FDA could make a decision on approval in August 2015. The New Drug Application was submitted under the agency's Fast Track program and is based on results from the landmark PARADIGM-HF study, the largest ever conducted in heart failure, which showed LCZ696 was superior to ACE-inhibitor enalapril on key endpoints, including significantly reducing the risk of CV death or heart failure hospitalization. Patients' reports of how well they felt were significantly better with LCZ696 than enalapril, whilst maintaining an acceptable safety profile. In the EU the Committee for Medicinal Products for Human Use has granted accelerated assessment to LCZ696.
10:28 EDTPFEPfizer announces FDA acceptance for review of NDA for ALO-02
Subscribe for More Information
10:00 EDTGSKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ametek (AME) upgraded to Outperform at RW Baird... Ascena Retail (ASNA) upgraded to Buy from Hold at KeyBanc... Cabela's (CAB) upgraded to Buy from Neutral at DA Davidson... CoreSite Realty (COR) upgraded to Overweight from Equal Weight at Stephens... Cytokinetics (CYTK) upgraded to Overweight from Neutral at Piper Jaffray... DTS, Inc. (DTSI) upgraded to Outperform at Cowen... Dr Pepper Snapple (DPS) upgraded to Market Perform from Underperform at Wells Fargo... Elizabeth Arden (RDEN) upgraded to Outperform from Market Perform at BMO Capital... EnLink Midstream (ENLC) upgraded to Buy from Hold at Wunderlich... GlaxoSmithKline (GSK) upgraded to Buy from Sell at UBS... Great-West Lifeco (GWLIF) upgraded to Buy from Hold at TD Securities... Himax (HIMX) upgraded to Buy from Neutral at Chardan... Mallinckrodt (MNK) upgraded to Overweight from Neutral at JPMorgan... Medical Properties upgraded to Outperform from Sector Perform at RBC Capital... Microchip (MCHP) upgraded to Buy from Hold at Drexel Hamilton... Orbitz (OWW) upgraded to Neutral from Sell at Goldman... Plains GP Holdings (PAGP) upgraded to Overweight from Equal Weight at Stephens... SanDisk (SNDK) upgraded to Buy from Hold at Drexel Hamilton... SkyWest (SKYW) upgraded to Buy from Hold at Deutsche Bank... Stage Stores (SSI) upgraded at Sterne Agee... Tractor Supply (TSCO) upgraded to Buy from Hold at Argus... Valero (VLO) upgraded to Conviction Buy from Neutral at Goldman... Watsco (WSO) upgraded to Overweight from Equal Weight at Stephens.
08:23 EDTGSK, NVSPiper Jaffray biotech/healthcare analysts hold analyst/industry conference call
Subscribe for More Information
08:19 EDTGSK, BIIB, CELG, PFEAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information
06:33 EDTGSKGlaxoSmithKline upgraded to Buy from Sell at UBS
Subscribe for More Information
05:38 EDTCELGCelgene volatility increases on wide price movement
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use